Abstract
Aims Red blood cell distribution width/albumin ratio (RAR) is a novel parameter associated with inflammation. Previous studies have not focused on the role of RAR in the incidence and long-term prognosis of chronic heart failure (CHF). This study included three cohorts, two prospective and one retrospective study. The aim was to investigate the value of RAR in the incidence of CHF and the long-term prognosis of CHF.
Methods Three cohorts were investigated, including MIMIC, NHANES, and JHDH. The included patients of MIMIC, NHANES, and JHDH were 22,672 from 2001-2012, 60,754 from 1999-2020, and 15,102 from 2021-2022, respectively. According to whether the patients have CHF-related risk factors, the patients were classified into non-CHF, pre-CHF, and CHF groups. The median follow-up time of MIMIC and NHANES was 364 days and 62 months. Logistic regression, Cox regression, restricted cubic spline (RCS), and Kaplan–Meier (KM) curves were used to analyze the value of RAR in CHF patients.
Result In NHANES, the CHF prevalence in quartiles of RAR (Q1, Q2, Q3, and Q4) were 8.88%, 16.86%, 27.65%, and 46.61%, respectively. MIMIC and JHDH showed a similar trend. Among the non-CHF and CHF patients, the odds ratio (OR) was 1.45 (JHDH 95% CI 1.33-1.58) and 1.93 (NHANES 95% CI 1.41-2.65). In NHANES, the RAR OR value of Q2, Q3 and Q4 were 2.02(CI 1.19-3.43), 3.24(CI 1.95-5.39), and 4.95(CI 2.44-10.02) compared with Q1, respectively. And the OR was 1.05 (MIMIC 95% CI 1.02-1.07) in pre-CHF and CHF patients. The CHF mortality showed an adjusted hazard ratio (HR) is 1.12 (MIMIC 95% CI 1.1-1.14) and 2.26 (NHANES 95% CI 1.52-3.36). KM demonstrates that higher RAR (>3.4 in NHANES and >5.06 in MIMIC) prognoses lead to poor survival in CHF patients. CHF mortality in the 19th quartile of the RAR was 1.4 times higher than in the first quartile, compared with 1.22 times in the red blood cell distribution width (RDW). The 19-quartile mortality curves of the RAR were more stable than RDW and albumin (ALB).
Conclusion RAR is an independent risk factor for incidence and all-cause long-term mortality in CHF patients. The predictive value of RAR for all-cause mortality in CHF is superior to ALB and RDW. RAR may be a potential clinical indicator for future treatment of CHF.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The clinical trial part was approved by the Ethics Review Committee of Jinghai District Hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The primary MIMIC data were downloaded from https://mimic.mit.edu/. And the primary NHANES data were derived from https://www.cdc.gov/nchs/nhanes/index.htm. And the data used or analyzed in this study and the original R code are available from the corresponding author upon request.